Health products policy and standards
Our team provides authoritative guidance and standards on quality, safety and efficacy of health products and supports countries to formulate evidence-based policies and ensure good practice throughout the value chain.
/health-product-policy-and-standards-(hps)/63022.jpg?sfvrsn=e93c78d1_9 "Ministry of Health staff at their office in Port Vila")
/health-product-policy-and-standards-(hps)/who_034416-sm.jpg?sfvrsn=fc08f9ca_4 "WHO_034416 sm")
/health-product-policy-and-standards-(hps)/70820.jpg?sfvrsn=6b0fda4c_1 "70820")
Expert Committees
Advisory groups
Databases
Publications
All →
3 October 2025
WHO Drug Information - Volume 39, No. 3
The Third issue of volume 39 for 2025 includes:Consultation Documents: Cefiderocol sulfate tosilate (cefiderocoli sulfas tosilatum) Cefiderocol powder...
23 September 2025
Availability, price and affordability of health technologies for the management of diabetes
The WHO list of priority medical devices for management of cardiovascular diseases and diabetes, https://iris.who.int/handle/10665/341967, describes those...
5 September 2025
The selection and use of essential medicines, 2025: WHO AWaRe (Access, Watch, Reserve) classification...
The AWaRe classification is intended as a tool for monitoring antibiotic use, defining targets and monitoring the impact of stewardship policies and interventions...
5 September 2025
The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines for Children,...
Essential medicines are those that satisfy the priority health care needs of a population. They are selected with due regard to disease prevalence and...
Journal articles
WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products: Seoul, Republic of Korea, 25–26 June 2019
Biologicals Volume 65, May 2020, Pages 50-59
WHO informal consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products: Seoul, Republic of Korea, 27–28 April 2017
Biologicals, Volume 52, March 2018, Pages 83-91
1st WHO International Standard antiserum to RSV: Availability and benefits for RSV vaccine development: Commentary on the collaborative study report published in the vaccine journal (Vaccine 2018 36: 7641-7649)
Vaccine, 2019 Jul 18; 37(31):4233-4235
